Futura Medical

Profitability in sight as partner preps for US launch

Lighthouse | 10 April 2024

Share this note

  • Preliminary FY23 financial results confirm revenues of £3.1m (FY22: nil), as already disclosed in the Trading Update (February 2024 Lighthouse). Details on expenses highlight that costs remain tightly controlled, with underlying OpEx (excluding share-based payments) slightly lower at £6.0m (FY22: £6.2m), albeit there has been a shift from R&D to G&A as the focus has moved to Eroxon commercialisation. Non-cash share-based payments increased to £2.7m (FY22: £0.7m). Cash at end-December 2023 of £7.7m (FY22: £4m) is expected to extend beyond the anticipated US Eroxon launch.
  • There is much focus on the timing of Eroxon’s potential US launch, and partner Haleon recently disclosed (with FY23 results in February during analyst Q&A) that US launch was expected “within the next 12 months”. As this is a new brand and product, launching into a new category, launch preparations are likely to be lengthy as these will need to be optimised to target the broad and multiple channels in US consumer health, and to develop messaging that will resonate with target audiences. This will be key to ensure a successful initial launch, and for longer-term momentum.
  • In Europe, Eroxon has already successfully taken a >20% share of approved ED (erectile dysfunction) treatments since launches by partner Cooper Consumer Health in the UK and Belgium in March 2023. Full launches in ten countries, including France, Italy, and Spain (where Eroxon has been available through on-line channels), have already occurred or are expected during H124, with further launches planned for H224. Eroxon was recently made available on prescription in England and Wales, which should help to raise awareness amongst healthcare professionals.
  • Going forwards, Futura’s strategy is focused on three core pillars: (1) Address growing needs within the OTC sexual health market; (2) Broaden the product range; and (3) Commit to strong shareholder returns, profitability and financial discipline. For 2024 the priorities will be to achieve further Eroxon approvals and launches whilst strengthening the supply chain, explore range extensions and new products, and deliver revenue growth plus profitability within the next 12 months. We expect Futura to remain focused on costs and do not expect any near-term fundraises to support these aims.

Trinity Delta view: Following the recent Trading Update, there are few surprises within Futura’s FY23 financial results, with costs remaining tightly controlled. Focus on the potential US launch by partner Haleon is understandable, given the US commercial opportunity is likely the most significant. Hence, comments that preparations towards the US launch are progressing well, together with Haleon confirming launch is expected within 12 months, are reassuring. Whilst there continue to be limited insights into re-ordering patterns, we believe partner Cooper could provide more details in due course as EU launches become more established. We continue to believe Futura is uniquely placed within UK healthcare, with no near-term cash needs, and a clear pathway to profitability and sustainable cash generation. Our current valuation is £363m, or 121p/share.

Lighthouse

10 April 2024

Price42.80p
Market Cap£129.02m
Primary exchangeAIM
SectorHealthcare
Company CodeFUM
Corporate clientYes

Company description

Futura Medical is the developer of innovative sexual health products; its core strength is in its research, development, and commercialisation of topically delivered gel formulations. Lead product Eroxon (MED3000) is approved as an OTC product for ED (erectile dysfunction) in Europe and the US.

Analysts

Lala Gregorek
lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner
pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Disclaimer

Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2024 Trinity Delta Research Limited. All rights reserved.